Skip to main content

ProAxsis, Diagenics Ink Distribution Deal

NEW YORK (360Dx) – Biomarker-based diagnostics firm ProAxsis has reached a deal for Diagenics to distribute its ProteaseTag Active Neutrophil Elastase Immunoassay in Great Britain and Ireland.

Financial and other terms of the agreement were not disclosed.

Based in Belfast, Northern Ireland, ProAxsis develops products for capturing, detecting, and measuring active protease biomarkers of disease. The Protease Tag Active NE Immunoassay, launched in 2016, measures only the active form of neutrophil elastase. In a statement, ProAxsis CEO David Ribeiro said that published work has demonstrated the utility of the assay to measure active NE in patients with respiratory disease and identifying those at greatest risk of developing pulmonary exacerbation.

The company also offers NEATstik, a rapid test for measuring active neutrophil elastase at the point of care. That test received CE marking earlier this month, ProAxsis said.

Diagenics is headquartered in England and specializes in distributing and providing technical support for diagnostic tests for allergies and immunology and endocrinology.